000			03007nam a22006377a 4500
008			210607s20202020 xxu||||| |||| 00| 0 eng d
022			_a1750-743X
024			_a10.2217/imt-2020-0139 [doi]
040			_aOvid MEDLINE(R)
099			_a32640856
245			_aA patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.
251			_aImmunotherapy. 12(12):861-867, 2020 08.
252			_aImmunotherapy. 12(12):861-867, 2020 08.
252			_zImmunotherapy. 12(12):861-867, 2020 08.
253			_aImmunotherapy
260			_c2020
260			_fFY2021
265			_sppublish
266			_d2020-09-02
268			_aImmunotherapy. 12(12):861-867, 2020 08.
269			_fFY2021
520			_aBackground: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.
546			_aEnglish
650			_a*Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
650			_a*Antineoplastic Agents/tu [Therapeutic Use]
650			_a*Imidazoles/tu [Therapeutic Use]
650			_a*Immunotherapy/mt [Methods]
650			_a*Melanoma/dt [Drug Therapy]
650			_a*Oximes/tu [Therapeutic Use]
650			_a*Pyridones/tu [Therapeutic Use]
650			_a*Pyrimidinones/tu [Therapeutic Use]
650			_aAntibodies, Monoclonal, Humanized/im [Immunology]
650			_aAntineoplastic Agents/im [Immunology]
650			_aCyclin-Dependent Kinase 4/ai [Antagonists & Inhibitors]
650			_aCyclin-Dependent Kinase 4/im [Immunology]
650			_aCyclin-Dependent Kinase 6/ai [Antagonists & Inhibitors]
650			_aCyclin-Dependent Kinase 6/im [Immunology]
650			_aHumans
650			_aImidazoles/im [Immunology]
650			_aMale
650			_aMelanoma/im [Immunology]
650			_aMiddle Aged
650			_aOximes/im [Immunology]
650			_aPyridones/im [Immunology]
650			_aPyrimidinones/im [Immunology]
650			_aTreatment Outcome
651			_aMedStar Washington Hospital Center
656			_aInternal Medicine Residency
656			_aPathology Residency
657			_aJournal Article
700			_aAlzeer, Ali Hazem
700			_aZaemes, Jacob
790			_aAlzeer A, Atkins M, Villa K, Zaemes J
856			_uhttps://dx.doi.org/10.2217/imt-2020-0139 _zhttps://dx.doi.org/10.2217/imt-2020-0139
942			_cART _dArticle
999			_c5510 _d5510